Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Appoints Digital Health Non-Exec Director

8 Sep 2016 07:00

RNS Number : 2460J
NetScientific PLC
08 September 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Wanda Strengthens its Board with Digital Health Non-Executive Director

 

Derek Newell brings decades of digital health expertise

 

London, UK - 08 September 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that one of its portfolio companies, Wanda, has appointed a new Non-Executive Director, Derek Newell, to its Board.

Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific and Chairman of Wanda, said: "Derek is a highly regarded and knowledgeable industry leader with vast experience in the field of innovative health technology. We are delighted that Wanda has further strengthened its Board with a digital health expert of his calibre."

 

The full text of the announcement issued by Wanda on 07 September 2016 is as follows:

 

 

 

Wanda Appoints Jiff CEO Derek Newell an Outside Director

Newell brings decades of digital health expertise to the Wanda board

 

SAN FRANCISCO - 07 September, 2016 - Wanda™, recognized for bringing new and proven technologies to home-centered care, today announced the appointment of Derek Newell as an outside director. Newell is currently CEO of Jiff, a provider of an enterprise health benefits platform.

 

"Derek pioneered the use of remote patient monitoring technologies and will be an invaluable addition to the Wanda board," said Steve Curd, Wanda's CEO. "As we continue to enhance the Wanda offering, I am confident that Derek will offer tremendous insights and provide us with a unique perspective as we continue to advance our technical, operational, and financial objectives."

 

Newell brings 20 years of experience as a leader of innovative health technology and service companies. Prior to joining Jiff as CEO, Newell was president and CEO of Robert Bosch Healthcare and worked with the management team to build Bosch into the world's largest remote patient monitoring company. Before Bosch he was CEO of remote patient monitoring company Health Hero Networks, which sold to Bosch in 2007. Health Hero Network was the first company to get an internet connected medical device approved by the FDA. Newell also served as chief marketing officer of LifeMasters, where he helped pioneer the first patient-centric disease management platform and built one of the largest disease management companies in the US. Derek holds graduate degrees in business and public health from UC Berkeley.

 "I'm deeply committed to advancing the development of innovative technologies that reduce the cost chronic disease and enhance the lives of individuals with chronic conditions," said Newell. "I am impressed with the potential of the Wanda platform to solve some of healthcare's toughest challenges, based on how elegantly it converges proven machine-learning analytics and behavioral science. Wanda's ability to deliver ongoing risk analysis and decision support is better equipping individuals to care for themselves and allowing clinicians to more efficiently engage with consumers who are in most need of their assistance."

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found at www.yourwanda.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALLFSRAVIDIIR
Date   Source Headline
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.